CliffBio
small molecule

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

Loss of exclusivity—loss of exclusivity
CompanyAlcon →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
Active ingredientDEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
StrengthEQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJuly 1986
Marketing statusDISCN

More from Alcon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE patent cliff — loss of exclusivity — | CliffBio